金吾财讯 | 据港交所12月12日披露，讯飞医疗科技通过港交所上市聆讯，华泰国际、广发融资（香港）和建银国际为联席保荐人。公司是一家人工智能赋能的医疗解决方案提供商。公司的产品及解决方案涵盖了从健康风险预警、早期筛查、诊断、治疗及治疗效果评估到出院后管理和慢性病管理的整个医疗服务周期，并且独立开发了支撑公司产品及解决方案的人工智能技术。根据弗若斯特沙利文的资料，公司2023年的收入规模在中国医疗人工智能行业中排名第一，市场份额为5.9%。科大讯飞（一家专注于核心人工智能技术研究的领先人工智能公司）为公司的控股股东。财务方面，公司2021-2023年及2024年上半年，分别录得收益3.72亿、4.72亿、5.56亿及2.29亿元人民币；同期对应研发开支为1.60亿、2.42亿、2.64亿及1.35亿元人民币；同期对应公司拥有人应占亏损8370.7万、1.89亿、1.45亿及1.30亿元人民币。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.